ArticleCell death discovery2026
ARHGAP21 enhances metastasis in hepatocellular carcinoma by inhibiting ubiquitination of filamin A.
Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Rho GTPase-activating protein 21 (ARHGAP21) plays a role in the occurrence and development of certain cancers, but its function in hepatocellular carcinoma (HCC) remains unclear. In this study, elevated ARHGAP21 expression was observed in both HCC cell lines and tissues and correlated with poor patient prognosis. Knockdown of ARHGAP21 suppressed HCC cell migration and invasion in vitro by regulating the actin cytoskeleton, while overexpression of ARHGAP21 had the opposite effect. In vivo, knockdown of ARHGAP21 inhibited HCC tumorigenesis and metastasis. Mechanistically, we demonstrated that ARHGAP21 directly binds to FLNA, and the PDZ domain of ARHGAP21 functions as a potential mediator of its binding to the 1-1200 aa fragment of FLNA. ARHGAP21 also directly binds to and recruits HSP90α to stabilize FLNA by inhibiting its ubiquitination and degradation. Overexpression of FLNA reversed the cytoskeleton remodeling-related suppression of tumor metastasis in ARHGAP21-knockdown HCC cells. These results revealed that ARHGAP21 promotes cytoskeleton remodeling and stimulates HCC metastasis by inhibiting FLNA ubiquitination and degradation via HSP90α recruitment. Our results position ARHGAP21 as both a potential prognostic marker and a promising therapeutic target in HCC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.